29 October 2019

Anna Häger and Peter Friedl, theme Cancer development and immune defense, and colleagues, identified a new niche of cancer cell survival and developed an integrin inhibition therapy to overcome resistance. They have published their results in the Journal of Experimental Medicine.

Cancer fatalities result from metastatic dissemination and therapy resistance, both processes that depend on signals from the tumor microenvironment. To identify how invasion and resistance programs cooperate, they used intravital microscopy of orthotopic sarcoma and melanoma xenografts. They demonstrate that these tumors invade collectively and that, specifically, cells within the invasion zone acquire increased resistance to radiotherapy, rapidly normalize DNA damage, and preferentially survive. Using a candidate-based approach to identify effectors of invasion-associated resistance, they targeted β1 and αVβ3/β5 integrins, essential extracellular matrix receptors in mesenchymal tumors, which mediate cancer progression and resistance. Combining radiotherapy with β1 or αV integrin monotargeting in invading tumors led to relapse and metastasis in 40–60% of the cohort, in line with recently failed clinical trials individually targeting integrins. However, when combined, anti-β1/αV integrin dual targeting achieved relapse-free radiosensitization and prevented metastatic escape. Collectively, invading cancer cells thus withstand radiotherapy and DNA damage by β1/αVβ3/β5 integrin cross-talk, but efficient radiosensitization can be achieved by multiple integrin targeting.
 

Related news items


Online intervention for women exposed to intimate partner violence

21 November 2019

Within the SAFE project from the department of Primary and Community Care an eHealth intervention has been developed for women exposed to intimate partner violence (IPV).

read more

A personal touch of Sander Leeuwenburgh

21 November 2019

In order to promote interaction amongst colleagues within RIMLS, we have a ‘personal touch’ series setting employees in the spotlight. A light-hearted manner to learn about the colleagues you know and those you don’t. This week: Sander Leeuwenburgh.

read more

Technology for Oncology II grant application funded

21 November 2019

The grant application called "aiREAD – Accurate and Intelligent Reading for EArlier breast cancer Detection” by project leader Ioannis Sechopoulos, has been selected for funding under the NWO TTW – KWF Kankerbestrijding – Top Sector LSH Partnership “Technology for Oncology II”.

read more

KNCV Golden Master Award call for nominations

20 November 2019

The Royal Netherlands Chemistry Society awards this prize each year to the best Master’s research project. The Master’s thesis must relate to research in the field of chemistry, life sciences, process technology or (bio-)molecular sciences. Deadline: 31-12-2019.

read more

Podosome nanoscale architecture redefined

20 November 2019

Koen van den Dries and Alessandra Cambi, theme Nanomedicine, revealed how the nanoscale architecture of podosomes enables dendritic cells to protrude and sense their extracellular environment. They have published their results in Nature Communications.

read more

270 times Homo Universalis in Nijmegen

20 November 2019

What does a scientist of the future look like? International young scientists addressed this important topic during the ENABLE conference, organized by young researchers for young researchers. They showed how the new generation of researchers wants to open up science to the public.

read more